BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis. 1995

M Kihara, and Y Ikeda, and N Takagi, and H Fujita, and K Shibata, and S Masumori, and K Shiratori, and S Umemura, and H Shionoiri, and M Ishii
Second Department of Internal Medicine, Yokohama Minami Kyousai Hospital, Japan.

OBJECTIVE The pharmacokinetics of amikacin were studied in patients undergoing slow hemodialysis (HD). METHODS Slow HD was performed at the dialysate flow rate of 30 ml/min. After a single intravenous dose of amikacin 5 mg/kg, pharmacokinetic variables were calculated by fitting individual concentration-time curves to a two-compartment open model. METHODS 6 critically ill patients with renal failure were entered into the study. RESULTS The volume of distribution was 0.35 +/- 0.03 l/kg. Total body clearance was 35.1 +/- 2.3 ml/min with an elimination half-life of 10.5 h. During a 10.5 h session of slow HD, the serum amikacin concentration decreased from the peak level of 21.3 +/- 1.2 mg/l to 7.2 +/- 0.9 mg/l. CONCLUSIONS Slow HD eliminate amikacin more efficiently than other types of slowly performed renal replacement therapy and had profound effects on the pharmacokinetics. Amikacin elimination by this approach should be taken into consideration for designing a dosage schedule during the treatment.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D003422 Critical Care Health care provided to a critically ill patient during a medical emergency or crisis. Intensive Care,Intensive Care, Surgical,Surgical Intensive Care,Care, Critical,Care, Intensive,Care, Surgical Intensive
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M Kihara, and Y Ikeda, and N Takagi, and H Fujita, and K Shibata, and S Masumori, and K Shiratori, and S Umemura, and H Shionoiri, and M Ishii
Hemodialysis of amikacin in critically ill patients.
May 1988, Critical care medicine,
M Kihara, and Y Ikeda, and N Takagi, and H Fujita, and K Shibata, and S Masumori, and K Shiratori, and S Umemura, and H Shionoiri, and M Ishii
Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients.
December 2016, The Journal of antimicrobial chemotherapy,
M Kihara, and Y Ikeda, and N Takagi, and H Fujita, and K Shibata, and S Masumori, and K Shiratori, and S Umemura, and H Shionoiri, and M Ishii
Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.
January 2015, European journal of clinical pharmacology,
M Kihara, and Y Ikeda, and N Takagi, and H Fujita, and K Shibata, and S Masumori, and K Shiratori, and S Umemura, and H Shionoiri, and M Ishii
Population pharmacokinetics of amikacin in critically ill patients.
July 1996, Antimicrobial agents and chemotherapy,
M Kihara, and Y Ikeda, and N Takagi, and H Fujita, and K Shibata, and S Masumori, and K Shiratori, and S Umemura, and H Shionoiri, and M Ishii
Amikacin population pharmacokinetics in critically ill Kuwaiti patients.
January 2013, BioMed research international,
M Kihara, and Y Ikeda, and N Takagi, and H Fujita, and K Shibata, and S Masumori, and K Shiratori, and S Umemura, and H Shionoiri, and M Ishii
Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
February 2013, European review for medical and pharmacological sciences,
M Kihara, and Y Ikeda, and N Takagi, and H Fujita, and K Shibata, and S Masumori, and K Shiratori, and S Umemura, and H Shionoiri, and M Ishii
Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients.
October 2014, Biopharmaceutics & drug disposition,
M Kihara, and Y Ikeda, and N Takagi, and H Fujita, and K Shibata, and S Masumori, and K Shiratori, and S Umemura, and H Shionoiri, and M Ishii
Single-dose pharmacokinetics of cefodizime in critically ill elderly patients.
April 2006, International journal of antimicrobial agents,
M Kihara, and Y Ikeda, and N Takagi, and H Fujita, and K Shibata, and S Masumori, and K Shiratori, and S Umemura, and H Shionoiri, and M Ishii
Pharmacokinetics of amikacin (BB-K8) in patients undergoing hemodialysis.
August 1979, International journal of clinical pharmacology and biopharmacy,
M Kihara, and Y Ikeda, and N Takagi, and H Fujita, and K Shibata, and S Masumori, and K Shiratori, and S Umemura, and H Shionoiri, and M Ishii
Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.
June 2018, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!